<DOC>
	<DOCNO>NCT01618734</DOCNO>
	<brief_summary>TPO-r Switch retrospective study patient affect Immune Thrombopenia ( ITP ) receive alternatively romiplostim eltrombopag .</brief_summary>
	<brief_title>Eltrombopag Romiplostim Used Alternatively Patients With Immune Thrombopenia ( ITP ) : Efficacy Safety .</brief_title>
	<detailed_description>Thrombopoietin mimetics agent available since 5 year France clinical trial first license . Two drug use : romiplostim eltrombopag . These molecule receptor megacaryocyte induce stimulation cell lead differentiation proliferation platelet . But romiplostim eltrombopag 2 different characteristic : way administration ( oral eltrombopag subcutaneous romiplostim ) bind site C-MPL receptor megacaryocyte . The aim study describe ITP patient receive two drug alternatively order know benefit switching molecule clinical practice .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Subject diagnosis ITP accord American Society Hematology guideline ( Rodeghiero et al , 2009 ) . Subject equal great 18 year age . Before studyspecific procedure , appropriate write informed consent must obtain . Subject receive romiplostim eltrombopag alternatively Available followup 2 month least period Secondary ITP e.g : thrombopenia related hepatitis C , HIV , Chronic Lymphocytic Leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>Thrombopoietin receptor agonist</keyword>
</DOC>